Logo image of CLSD

CLEARSIDE BIOMEDICAL INC (CLSD) Stock Fundamental Analysis

NASDAQ:CLSD - Nasdaq - US1850631045 - Common Stock - Currency: USD

0.824  +0 (+0.44%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CLSD. CLSD was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CLSD have multiple concerns. While showing a medium growth rate, CLSD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLSD has reported negative net income.
In the past year CLSD has reported a negative cash flow from operations.
In the past 5 years CLSD reported 4 times negative net income.
CLSD had a negative operating cash flow in each of the past 5 years.
CLSD Yearly Net Income VS EBIT VS OCF VS FCFCLSD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

CLSD has a Return On Assets of -156.66%. This is amonst the worse of the industry: CLSD underperforms 85.13% of its industry peers.
Industry RankSector Rank
ROA -156.66%
ROE N/A
ROIC N/A
ROA(3y)-98.81%
ROA(5y)-77.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLSD Yearly ROA, ROE, ROICCLSD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200 -300

1.3 Margins

CLSD's Gross Margin of 89.45% is amongst the best of the industry. CLSD outperforms 92.82% of its industry peers.
CLSD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLSD Yearly Profit, Operating, Gross MarginsCLSD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K -250K

More info and screens

3

2. Health

2.1 Basic Checks

CLSD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLSD has more shares outstanding
CLSD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CLSD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLSD Yearly Shares OutstandingCLSD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLSD Yearly Total Debt VS Total AssetsCLSD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -28.77, we must say that CLSD is in the distress zone and has some risk of bankruptcy.
CLSD's Altman-Z score of -28.77 is on the low side compared to the rest of the industry. CLSD is outperformed by 84.62% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28.77
ROIC/WACCN/A
WACC9.8%
CLSD Yearly LT Debt VS Equity VS FCFCLSD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

CLSD has a Current Ratio of 3.19. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.
CLSD has a Current ratio (3.19) which is comparable to the rest of the industry.
CLSD has a Quick Ratio of 3.19. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.
CLSD has a Quick ratio (3.19) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.19
Quick Ratio 3.19
CLSD Yearly Current Assets VS Current LiabilitesCLSD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.64% over the past year.
Looking at the last year, CLSD shows a very negative growth in Revenue. The Revenue has decreased by -55.48% in the last year.
The Revenue has been decreasing by -5.17% on average over the past years.
EPS 1Y (TTM)22.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)-55.48%
Revenue growth 3Y-61.68%
Revenue growth 5Y-5.17%
Sales Q2Q%913.04%

3.2 Future

The Earnings Per Share is expected to grow by 21.27% on average over the next years. This is a very strong growth
Based on estimates for the next years, CLSD will show a very strong growth in Revenue. The Revenue will grow by 147.00% on average per year.
EPS Next Y5.45%
EPS Next 2Y-17.64%
EPS Next 3Y-4.26%
EPS Next 5Y21.27%
Revenue Next Year68.31%
Revenue Next 2Y78.01%
Revenue Next 3Y110.58%
Revenue Next 5Y147%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLSD Yearly Revenue VS EstimatesCLSD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CLSD Yearly EPS VS EstimatesCLSD Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLSD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLSD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLSD Price Earnings VS Forward Price EarningsCLSD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLSD Per share dataCLSD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as CLSD's earnings are expected to decrease with -4.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.64%
EPS Next 3Y-4.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLSD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARSIDE BIOMEDICAL INC

NASDAQ:CLSD (6/24/2025, 1:19:02 PM)

0.824

+0 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners14.32%
Inst Owner Change-2.8%
Ins Owners7.52%
Ins Owner Change0.18%
Market Cap64.03M
Analysts84.62
Price Target5.54 (572.33%)
Short Float %0.18%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.13%
Min EPS beat(2)-0.93%
Max EPS beat(2)0.67%
EPS beat(4)3
Avg EPS beat(4)12.06%
Min EPS beat(4)-0.93%
Max EPS beat(4)27.38%
EPS beat(8)5
Avg EPS beat(8)6.63%
EPS beat(12)6
Avg EPS beat(12)-20.66%
EPS beat(16)9
Avg EPS beat(16)-11.73%
Revenue beat(2)2
Avg Revenue beat(2)656.76%
Min Revenue beat(2)69.81%
Max Revenue beat(2)1243.71%
Revenue beat(4)3
Avg Revenue beat(4)502.87%
Min Revenue beat(4)-30.34%
Max Revenue beat(4)1243.71%
Revenue beat(8)6
Avg Revenue beat(8)389.96%
Revenue beat(12)7
Avg Revenue beat(12)263.57%
Revenue beat(16)10
Avg Revenue beat(16)197.85%
PT rev (1m)-4.2%
PT rev (3m)-9.52%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)-7.71%
EPS NY rev (1m)1.02%
EPS NY rev (3m)7.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)73.33%
Revenue NY rev (1m)136.79%
Revenue NY rev (3m)-12.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.05
BVpS-0.59
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -156.66%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.45%
FCFM N/A
ROA(3y)-98.81%
ROA(5y)-77.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 328.27%
Cap/Sales 24.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.19
Quick Ratio 3.19
Altman-Z -28.77
F-Score2
WACC9.8%
ROIC/WACCN/A
Cap/Depr(3y)1083.74%
Cap/Depr(5y)656.91%
Cap/Sales(3y)33.04%
Cap/Sales(5y)19.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y5.45%
EPS Next 2Y-17.64%
EPS Next 3Y-4.26%
EPS Next 5Y21.27%
Revenue 1Y (TTM)-55.48%
Revenue growth 3Y-61.68%
Revenue growth 5Y-5.17%
Sales Q2Q%913.04%
Revenue Next Year68.31%
Revenue Next 2Y78.01%
Revenue Next 3Y110.58%
Revenue Next 5Y147%
EBIT growth 1Y-1.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.65%
EBIT Next 3Y-31.28%
EBIT Next 5YN/A
FCF growth 1Y4.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.29%
OCF growth 3YN/A
OCF growth 5YN/A